Ductal adenocarcinoma of the prostate gland

From Libre Pathology
Jump to navigation Jump to search
Ductal adenocarcinoma of the prostate gland
Diagnosis in short

Ductal adenocarcinoma of prostate. H&E stain. (WC)

Synonyms prostatic ductal adenocarcinoma, endometrioid adenocarcinoma (use discouraged), papillary adenocarcinoma of prostate (old term)
Subtypes (subtype of prostate carcinoma)
LM DDx acinar adenocarcinoma of prostate, prostatic-type polyp, adenocarcinoma of the urinary bladder, metastatic adenocarcinoma
IHC chromogranin A +ve, p53 +ve, PSA +ve
Grossing notes prostate biopsy, prostate chips, radical prostatectomy
Staging prostate cancer staging
Site prostate gland - esp. central zone, see prostate cancer

Prevalence uncommon - though considered most common non-acinar prostate carcinoma
Prognosis poor

Ductal adenocarcinoma of the prostate gland, also prostatic ductal adenocarcinoma, is relatively common variant of prostate cancer.

It is also known as prostatic adenocarcinoma, large duct type.

It should not be confused with intraductal carcinoma of the prostate gland.

General

  • Sometimes it is referred to as endometrioid or endometrial adenocarcinoma; both terms are discouraged.[1]
  • In older literature it is referred to as papillary adenocarcinoma of the prostate.[2][3]
  • Not completely uncontroversial - may represent acinar adenocarcinoma with periurethral ducts involvement.[4]
  • More aggressive than conventional (acinar) prostate carcinoma.

Microscopic

Features:[5]

  1. Pseudostratified (crowded appearing) columnar (or cigar-shaped) nuclei - key feature.
  2. Compatible architecture:
  3. >= 50% of tumour.[6] ‡‡
    • If ductal component <50%, it is a conventional (acinar) adenocarcinoma with a ductal component.

Notes:

  • Proportion of ductal component should be quantified:
    • <10% ductal component of no prognostic significance.[6]
  • ‡‡ Mahul Amin advocates that >=80% should be ductal morphology to call ductal adenocarcinoma.[7]

DDx:

Images

www

IHC

Features:[8]

  • p53 +ve in ~ 75% of cases.
  • Ki-67 high in ~ 70% of cases.
  • Chromogranin A +ve (cytoplasm) in ~ 70% of cases.

Others:[9]

  • PSA +ve.

See also

References

  1. Samaratunga, H.; Delahunt, B. (Aug 2008). "Ductal adenocarcinoma of the prostate: current opinion and controversies.". Anal Quant Cytol Histol 30 (4): 237-46. PMID 18773743.
  2. Miki, J.; Ikemoto, I.; Shimomura, T.; Kiyota, H.; Oisi, Y.; Kondo, I.; Madarame, J.; Endo, K. et al. (Jan 2003). "[Papillary adenocarcinoma of the prostate: report of 4 cases].". Hinyokika Kiyo 49 (1): 21-4. PMID 12629776.
  3. Wernert, N.; Lüchtrath, H.; Seeliger, H.; Schäfer, M.; Goebbels, R.; Dhom, G. (1987). "Papillary carcinoma of the prostate, location, morphology, and immunohistochemistry: the histogenesis and entity of so-called endometrioid carcinoma.". Prostate 10 (2): 123-31. PMID 2436204.
  4. Bock, BJ.; Bostwick, DG. (Jul 1999). "Does prostatic ductal adenocarcinoma exist?". Am J Surg Pathol 23 (7): 781-5. PMID 10403300.
  5. Zhou, Ming; Magi-Galluzzi, Cristina (2006). Genitourinary Pathology: A Volume in Foundations in Diagnostic Pathology Series (1st ed.). Churchill Livingstone. pp. 88. ISBN 978-0443066771.
  6. 6.0 6.1 Amin, A.; Epstein, JI. (Apr 2011). "Pathologic stage of prostatic ductal adenocarcinoma at radical prostatectomy: effect of percentage of the ductal component and associated grade of acinar adenocarcinoma.". Am J Surg Pathol 35 (4): 615-9. doi:10.1097/PAS.0b013e31820eb25b. PMID 21383610.
  7. Amin, Mahul B. (2010). Diagnostic Pathology: Genitourinary (1st ed.). Amirsys. pp. 3-102. ISBN 978-1931884280.
  8. Tarján, M.; Lenngren, A.; Hellberg, D.; Tot, T. (Jun 2012). "Immunohistochemical verification of ductal differentiation in prostate cancer.". APMIS 120 (6): 510-8. doi:10.1111/j.1600-0463.2011.02862.x. PMID 22583364.
  9. Kumar, A.; Mukherjee, SD. (Apr 2010). "Metastatic ductal carcinoma of the prostate: a rare variant responding to a common treatment.". Can Urol Assoc J 4 (2): E50-4. PMID 20368883.